Skip to main content
VCbacked
Log inGet Started

Mitoimmune Therapeutics

Seoul, South Korea

Mito Immune Therapeutics is a drug research and development biotech company.

$3.9M raised
Sep 2023
Venture - Series Unknown
BiotechnologyMedicalPharmaceutical

Top Investors

Quantum Ventures KoreaIMM InvestmentSL InvestmentKorea Development BankKB Investment

Founder Contacts

19,000+ verified contacts
Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Mitoimmune Therapeutics

How much funding has Mitoimmune Therapeutics raised?
Mitoimmune Therapeutics has raised $3.9M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in September 2023.
Who are Mitoimmune Therapeutics's investors?
Mitoimmune Therapeutics's investors include Quantum Ventures Korea, IMM Investment, SL Investment, Korea Development Bank, KB Investment.
Where is Mitoimmune Therapeutics headquartered?
Mitoimmune Therapeutics is headquartered in Seoul, South Korea.
What does Mitoimmune Therapeutics do?
Mito Immune Therapeutics is a drug research and development biotech company.
What stage is Mitoimmune Therapeutics at?
Mitoimmune Therapeutics is at the Venture - Series Unknown stage.
Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"Mitoimmune Therapeutics — Funding & Investors." VCBacked, September 21, 2023, https://www.vcbacked.co/company/mitoimmune-therapeutics. Accessed June 8, 2026.
APA
VCBacked. (2023). Mitoimmune Therapeutics — Funding & Investors. Retrieved June 8, 2026, from https://www.vcbacked.co/company/mitoimmune-therapeutics
Wikipedia (cite web)
{{cite web |title=Mitoimmune Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/mitoimmune-therapeutics |website=VCBacked |access-date=June 8, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated .

Similar Companies in Biotechnology

View all
Virtuoso Surgical
Nashville
Pharvaris
Zug
Odyssey Therapeutics
Boston$213.0M
Tempus
Chicago
Anagram Therapeutics
Boston
Prenetics
Hong Kong